Bertolino J G
Department of Family Practice, University of Kentucky College of Medicine, Lexington 40536-0226.
Postgrad Med. 1990 Jul;88(1):183-6. doi: 10.1080/00325481.1990.11716370.
Transient leukopenia and, less commonly, neutropenia may occur with carbamazepine therapy. Discontinuation of therapy is usually not indicated unless symptoms are severe, persistent, or accompanied by infection. Patients with a low leukocyte or neutrophil count before treatment may be at increased risk for carbamazepine-induced leukopenia or neutropenia. Careful monitoring of blood counts, particularly during the first month of therapy, is essential. The frequency of monitoring can be determined on an individual basis. If a hematologic abnormality develops, the frequency of monitoring should be increased, especially if carbamazepine is not discontinued. Only when the neutrophil count falls below 500/mm3 does a severe risk of infection exist.
卡马西平治疗可能会出现短暂性白细胞减少，较少见的是中性粒细胞减少。通常无需停药，除非症状严重、持续或伴有感染。治疗前白细胞或中性粒细胞计数低的患者发生卡马西平诱导的白细胞减少或中性粒细胞减少的风险可能会增加。仔细监测血细胞计数至关重要，尤其是在治疗的第一个月。监测频率可根据个体情况确定。如果出现血液学异常，应增加监测频率，尤其是在未停用卡马西平的情况下。只有当中性粒细胞计数降至500/mm3以下时，才存在严重的感染风险。
